News
-
AstraZeneca to keep Zoladex on PBS longer
- Wed Sep 23
AstraZeneca will keep Zoladex on the PBS for another six months but after that, the product will be withdrawn from Australia.
Read more -
Patients asked back to HTA reform table
- Wed Sep 23
Despite having made endless contributions over the past seven years, the Department is asking patients to return to the table – again.
Read more -
Takeda’s narcolepsy therapy on TGA fast track
- Wed Sep 23
Takeda leads latest batch of TGA evaluations as new and existing therapies advance under priority, orphan and provisional pathways.
Read more -
MA Board candidates make their pitch
- Mon Sep 21
EXCLUSIVE: Nomination statements for all three candidates contesting two director vacancies on the Medicines Australia Board – published in full.
Read more -
How MFN hands MA exactly what it needs
- Mon Sep 21
Medicines Australia enters negotiations with more leverage than at any point in history, reshaping the stakes for government and the GBMA.
Read more -
In defence of the humble omnibus survey
- Mon Sep 21
In response to an op-ed on omnibus surveys, The Advisory Ward’s Will Collie argues they are of value – it all depends on the question.
Read more -
Butler funds new PBS options for patients
- Mon Sep 21
Two more listings announced for October, Arrotex securing funding for an eczema cream that will benefit an estimated 100,000 patients.
Read more -
The playbook guiding MA’s negotiations
- Fri Sep 18
Medicines Australia’s contracted negotiator outlines how his organisation helped ink a deal in the UK, including tactics and policy signals.
Read more